ArticleScientific reports2025
NR4A1 expression aberrations contribute to radiotherapy resistance in gastric cancer.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Gastric cancer (GC) is a common and life-threatening malignancy. It is often diagnosed at advanced stages. A major challenge in treatment is the development of radiotherapy resistance. This resistance significantly reduces the effectiveness of therapy. Therefore, our objective is to pinpoint genes linked to the resistance against radiotherapy in gastric cancer. The NR4A1 expression exhibited abnormalities in radioresistant gastric cancer cells, specifically MKN45-R and AGS-R cells, in comparison to their respective parental cells. Through high-throughput sequencing, we screened these cells and utilized quantitative reverse transcription-polymerase chain reaction analysis (qRT-PCR) to quantify NR4A1 expression. Functional analyses of NR4A1 in GC radioresistance were conducted by overexpressing NR4A1 in both MKN45-R and AGS-R cells, as well as their parental counterparts. Finally, the clinical relevance of NR4A1 in GC was confirmed through animal experiments. The expression of NR4A1 was significantly reduced in radioresistant cells, namely MKN45-R and AGS-R, as opposed to their parental counterparts. Overexpressing NR4A1 in MKN45-R and AGS-R cells resulted in heightened sensitivity to radiation. Additionally, NR4A1 overexpression exerted inhibitory effects on the growth and metastasis of GC tissues in animal models following irradiation (IR). Our observations indicate that NR4A1 plays a crucial role in enhancing the radiation sensitivity of gastric cancer cells, underscoring the therapeutic potential of NR4A1 in GC treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.